A total of @ women ( @ in the pegfilgrastim group and @ in the placebo group ) between @ and @ years of age with stage I-III invasive breast carcinoma who were to receive TC chemotherapy ( docetaxel @ mg/m ( @ ) and cyclophosphamide @ mg/m ( @ ) every @ weeks ) as either neoadjuvant or adjuvant therapy were enrolled ; @ of these patients were treated with either pegfilgrastim ( n = @ ) or placebo ( n = @ ) .